Ｅｘｐｒｅｓｓｉｏｎ ｏｆ ＫＭＴ２Ｄ ｉｎ ｐａｔｉｅｎｔｓ ｗｉｔｈ ｐｒｏｓｔａｔｅ ｃａｎｃｅｒ ａｎｄ ｉｔｓ ｒｅｌａｔｉｏｎｓｈｉｐ ｗｉｔｈ ｃｌｉｎｉｃｏｐａｔｈｏｌｏｇｉｃａｌ ｃｈａｒａｃｔｅｒｉｓｔｉｃｓ ａｎｄ
ｐｒｏｇｎｏｓｉｓ Ｌｉ Ｈｏｎｇｂｉｎ， Ｈｅ Ｂａｏｚｈｏｎｇ， Ｈｏｕ Ｌｉｎ， Ｆｅｎｇ Ｄｏｎｇ， Ｆａｎ Ｍａｏｙｕ． Ｄｅｐａｒｔｍｅｎｔ ｏｆ ｔｈｅ Ｆｉｆｔｈ Ｐｅｏｐｌｅ＇ｓ Ｈｏｓｐｉｔａｌ ｏｆ Ｄａ⁃
ｔｏｎｇ， Ｓｈａｎｘｉ Ｐｒｏｖｉｎｃｅ， Ｄａｔｏｎｇ ０３７０００，Ｃｈｉｎａ
Ｃｏｒｒｅｓｐｏｎｄｉｎｇ ａｕｔｈｏｒ： Ｈｅ Ｂａｏｚｈｏｎｇ， Ｅ⁃ｍａｉｌ： ＨＢＺ２２１３＠ ｓｏｈｕ． ｃｏｍ
Ｆｕｎｄｉｎｇ ｐｒｏｇｒａｍ： Ｋｅｙ Ｒ＆Ｄ Ｐｌａｎ Ｐｒｏｊｅｃｔ ｏｆ Ｓｈａｎｘｉ Ｐｒｏｖｉｎｃｅ （２０１９０３Ｄ３２１１５７）

Abstract：

Objective To investigate the expression of histone lysine methyltransferase 2D(KMT2D) in patients with prostate cancer and its relationship with clinicopathological characteristics and prognosis. Methods A total of 126 patients with prostate cancer undergoing radical prostatectomy in the Urological Department of the Fifth People's Hospital of Datong City, Shanxi Province, from July 2015 to July 2017 were selected as the observation group, and were divided into a subgroup with good prognosis(n=88) and a subgroup with poor prognosis(n=38) based on the 3-year follow-up. In addition, 120 health examination volunteers from the same hospital were selected as the health control group. Clinical data of subjects were collected, and serum KMT2D expression levels were measured using real-time fluorescence quantitative PCR(qRT-PCR). Cox regression analysis was used to analyze factors that affect the prognosis of prostate cancer patients. The predictive value of serum KMT2D for poor prognosis of prostate cancer was analyzed using subject performance characteristic curve(ROC). Results The serum KMT2D level in the observation group was higher than that in the healthy control group(t/P=8.504/<0.001); The serum KMT2D level in the poor prognosis subgroup was higher than that in the good prognosis subgroup(t/P=6.601/<0.001); the="" relative="" expression="" of="" kmt2d="" in="" prostate="" cancer="" patients="" with="" gleason="" score="">7, microvascular invasion, TNM stage III, and lymph node metastasis was significantly higher than those with Gleason score ≤ 7, microvascular invasion, TNM stage I-II, and lymph node metastasis, respectively(t/P=3.958/<0.001, 2.292/0.024, 3.022/0.003, 5.982/<0.001); The 3-year survival rate of patients with low expression of KMT2D is significantly higher than that of patients with high expression of KMT2D(χ²/P=10.112/0.001);Cox regression analysis showed that high expression of KMT2D, Gleason score>7, TNM stage III, and lymph node metastasis were risk factors for poor prognosis in prostate cancer patients [OR(95%CI)=1.245(1.019-1.521), 1.063(1.010-1.119), 1.152(1.053-1.261), 1.474(1.127-1.928)]. ROC curve analysis showed that the area under the curve(AUC) of serum KMT2D for predicting poor prognosis in prostate cancer patients was 0.814, the sensitivity was 0.680, the specificity was 0.908, and the Jordan index was 0.588. Conclusion KMT2D is highly expressed in the serum of prostate cancer patients, which has a good predictive value for poor prognosis and is a risk factor for poor prognosis.

Prostate cancer;                    Histone-lysine N-methyltransferase 2D;                    Clinicopathological characteristics;                    Prognosis;                    Correlation;